Unit
Rheumatologie
RHEUMA · Dept. I
Cutaneous manifestations of lymphoid-variant hypereosinophilic syndrome.
Laurent C, Lefèvre G, Kahn J, Staumont-Salle D, Felten R, Puget M, Moulinet T, Machelart I, Launay D, Charvet E, Bouaziz J, Jachiet M, Espitia A, Mahr A, Le Clech C, Malphettes M, Morice C, Mourah S, Moins-Teisserenc H, Lifermann F, Soulier-Guérin K, Villate A, Baillou C, Grados A, Robbins A, Abisror N, Bagot M, Boutboul D, Panel K, Vignon-Pennamen M, Rivet J, Battistella M, Groh M, de Masson A. Cutaneous manifestations of lymphoid-variant hypereosinophilic syndrome. Br J Dermatol 2022; 187:1011-1013.
Aug 12, 2022Cutaneous manifestations of lymphoid-variant hypereosinophilic syndrome.
Aug 12, 2022Br J Dermatol 2022; 187:1011-1013
Laurent Claire, Lefèvre Guillaume, Kahn Jean-Emmanuel, Staumont-Salle Delphine, Felten Renaud, Puget Marie, Moulinet Thomas, Machelart Irène, Launay David, Charvet Estelle, Bouaziz Jean David, Jachiet Marie, Espitia Alexandra, Mahr Alfred, Le Clech Christian, Malphettes Marion, Morice Cécile, Mourah Samia, Moins-Teisserenc Hélène, Lifermann François, Soulier-Guérin Karine, Villate Alban, Baillou Chloé, Grados Aurélie, Robbins Ailsa, Abisror Noemie, Bagot Martine, Boutboul David, Panel Kewin, Vignon-Pennamen Marie-Dominique, Rivet Jacqueline, Battistella Maxime, Groh Matthieu, de Masson Adèle
[ORAL SURVEILLANCE: what has changed in the risk assessment of JAK inhibitors?].
Rubbert-Roth A. [ORAL SURVEILLANCE: what has changed in the risk assessment of JAK inhibitors?]. Z Rheumatol 2022; 81:780-781.
Aug 12, 2022[ORAL SURVEILLANCE: what has changed in the risk assessment of JAK inhibitors?].
Aug 12, 2022Z Rheumatol 2022; 81:780-781
Rubbert-Roth Andrea
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.
Aletaha D, Kerschbaumer A, Kastrati K, Dejaco C, Dougados M, McInnes I, Sattar N, Stamm T, Takeuchi T, Trauner M, van der Heijde D, Voshaar M, Winthrop K, Ravelli A, Betteridge N, Burmester G, Bijlsma J, Bykerk V, Caporali R, Choy E, Codreanu C, Combe B, Crow M, de Wit M, Emery P, Fleischmann R, Gabay C, Hetland M, Hyrich K, Iagnocco A, Isaacs J, Kremer J, Mariette X, Merkel P, Mysler E, Nash P, Nurmohamed M, Pavelka K, Poór G, Rubbert-Roth A, Schulze-Koops H, Strangfeld A, Tanaka Y, Smolen J. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Ann Rheum Dis 2022
Aug 11, 2022Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.
Aug 11, 2022Ann Rheum Dis 2022
Aletaha Daniel, Kerschbaumer Andreas, Kastrati Kastriot, Dejaco Christian, Dougados Maxime, McInnes Iain B, Sattar Naveed, Stamm Tanja, Takeuchi Tsutomu, Trauner Michael, van der Heijde Désirée, Voshaar Marieke, Winthrop Kevin, Ravelli Angelo, Betteridge Neil, Burmester Gerd-Rüdiger, Bijlsma Johannes Wj, Bykerk Vivian, Caporali Roberto, Choy Ernest H S, Codreanu Catalin, Combe Bernard, Crow Mary K, de Wit Maarten, Emery Paul, Fleischmann Roy, Gabay Cem, Hetland Merete Lund, Hyrich Kimme L, Iagnocco Annamaria, Isaacs John D, Kremer Joel M, Mariette Xavier, Merkel Peter A, Mysler Eduardo F, Nash Peter, Nurmohamed Michael T, Pavelka Karel, Poór Gyula, Rubbert-Roth Andrea, Schulze-Koops Hendrik, Strangfeld Anja, Tanaka Yoshiya, Smolen Josef S
Incidence of giant cell arteritis in six districts of Paris, France (2015-2017).
Gonzalez Chiappe S, Lechtman S, Maldini C, Mekinian A, Papo T, Sené T, Mahr A. Incidence of giant cell arteritis in six districts of Paris, France (2015-2017). Rheumatol Int 2022; 42:1721-1728.
Jul 12, 2022Incidence of giant cell arteritis in six districts of Paris, France (2015-2017).
Jul 12, 2022Rheumatol Int 2022; 42:1721-1728
Gonzalez Chiappe Solange, Lechtman Sarah, Maldini Carla Soledad, Mekinian Arsène, Papo Thomas, Sené Thomas, Mahr Alfred
Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study.
Hatemi G, Mahr A, Takeno M, Kim D, Melikoğlu M, Cheng S, McCue S, Paris M, Chen M, Yazici Y. Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study. RMD Open 2022; 8
Jul 1, 2022Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study.
Jul 1, 2022RMD Open 2022; 8
Hatemi Gülen, Mahr Alfred, Takeno Mitsuhiro, Kim Doyoung, Melikoğlu Melike, Cheng Sue, McCue Shannon, Paris Maria, Chen Mindy, Yazici Yusuf
[Behçet's disease].
Mahr A. [Behçet's disease]. Ther Umsch 2022; 79:269-276.
Jun 1, 2022[Behçet's disease].
Jun 1, 2022Ther Umsch 2022; 79:269-276
Mahr Alfred
[ANCA-Associated Vasculitides].
Stegert M, Neumann T, Daikeler T. [ANCA-Associated Vasculitides]. Ther Umsch 2022; 79:229-237.
Jun 1, 2022[ANCA-Associated Vasculitides].
Jun 1, 2022Ther Umsch 2022; 79:229-237
Stegert Mihaela, Neumann Thomas, Daikeler Thomas
The Sound of Interconnectivity; The European Vasculitis Society 2022 Report.
Egan A, Kronbichler A, Neumann I, Bettiol A, Carlson N, Cid M, Emmi G, Gopaluni S, Harper L, Hauser T, Little M, Luqmani R, Mahr A, McClure M, Mohammad A, Nelveg-Kristensen K, Ohlsson S, Peh C, Rutherford M, Alamo B, Scott J, Segelmark M, Smith R, Szpirt W, Tomasson G, Trivioli G, Vaglio A, Walsh M, Wester Trejo M, Westman K, Bajema I, Jayne D. The Sound of Interconnectivity; The European Vasculitis Society 2022 Report. Kidney Int Rep 2022; 7:1745-1757.
May 25, 2022The Sound of Interconnectivity; The European Vasculitis Society 2022 Report.
May 25, 2022Kidney Int Rep 2022; 7:1745-1757
Egan Allyson C, Kronbichler Andreas, Neumann Irmgard, Bettiol Alessandra, Carlson Nicholas, Cid María C, Emmi Giacomo, Gopaluni Seerapani, Harper Lorraine, Hauser Thomas, Little Mark A, Luqmani Raashid A, Mahr Alfred, McClure Mark, Mohammad Aladdin J, Nelveg-Kristensen Karl Emil, Ohlsson Sophie, Peh Chen Au, Rutherford Matthew, Alamo Beatriz Sanchez, Scott Jennifer, Segelmark Mårten, Smith Rona M, Szpirt Wladimir M, Tomasson Gunnar, Trivioli Giorgio, Vaglio Augusto, Walsh Michael, Wester Trejo Maria, Westman Kerstin, Bajema Ingeborg M, Jayne David R W
An international Delphi exercise to identify items of importance for measuring response to treatment in ANCA-associated vasculitis.
Quinn K, Monti S, Christensen R, Jayne D, Langford C, Lanier G, Mahr A, Pagnoux C, Shea B, Viðarsdóttir M, Tomasson G, Merkel P. An international Delphi exercise to identify items of importance for measuring response to treatment in ANCA-associated vasculitis. Semin Arthritis Rheum 2022; 55:152021.
Apr 28, 2022An international Delphi exercise to identify items of importance for measuring response to treatment in ANCA-associated vasculitis.
Apr 28, 2022Semin Arthritis Rheum 2022; 55:152021
Quinn Kaitlin A, Monti Sara, Christensen Robin, Jayne David, Langford Carol A, Lanier Georgia E, Mahr Alfred, Pagnoux Christian, Shea Beverley, Viðarsdóttir Maria Bjork, Tomasson Gunnar, Merkel Peter A
Update Immunglobulin-AVaskulitis
Neumann T. Update Immunglobulin-AVaskulitis. Z Rheumatol 2022; 2022:305-312.
Mar 18, 2022Update Immunglobulin-AVaskulitis
Mar 18, 2022Z Rheumatol 2022; 2022:305-312
Neumann Thomas
[Update on immunoglobulin A vasculitis].
Neumann T. [Update on immunoglobulin A vasculitis]. Z Rheumatol 2022; 81:305-312.
Mar 18, 2022[Update on immunoglobulin A vasculitis].
Mar 18, 2022Z Rheumatol 2022; 81:305-312
Neumann Thomas
Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline.
Zeng L, Walsh M, Guyatt G, Siemieniuk R, Collister D, Booth M, Brown P, Farrar L, Farrar M, Firth T, Fussner L, Kilian K, Little M, Mavrakanas T, Mustafa R, Piram M, Stamp L, Xiao Y, Lytvyn L, Agoritsas T, Vandvik P, Mahr A. Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline. BMJ 2022; 376:e064597.
Feb 25, 2022Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline.
Feb 25, 2022BMJ 2022; 376:e064597
Zeng Linan, Walsh Michael, Guyatt Gordon, Siemieniuk Reed A C, Collister David, Booth Michelle, Brown Paul, Farrar Lesha, Farrar Mark, Firth Tracy, Fussner Lynn A, Kilian Karin, Little Mark A, Mavrakanas Thomas A, Mustafa Reem A, Piram Maryam, Stamp Lisa K, Xiao Yingqi, Lytvyn Lyubov, Agoritsas Thomas, Vandvik Per O, Mahr Alfred
Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis: a systematic review.
Xiao Y, Guyatt G, Zeng L, Rw Jayne D, A Merkel P, Ac Siemieniuk R, Dookie J, A Buchan T, Ahmed M, J Couban R, Mahr A, Walsh M. Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis: a systematic review. BMJ Open 2022; 12:e050507.
Feb 25, 2022Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis: a systematic review.
Feb 25, 2022BMJ Open 2022; 12:e050507
Xiao Yingqi, Guyatt Gordon, Zeng Linan, Rw Jayne David, A Merkel Peter, Ac Siemieniuk Reed, Dookie Jared E, A Buchan Tayler, Ahmed Muhammad Muneeb, J Couban Rachel, Mahr Alfred, Walsh Michael
Eosinophilic granulomatosis with polyangiitis (EGPA) with low activity EBV replication during the COVID 19 pandemic.
Mueller M, Poller W, Klingel K, Neumann T, Landmesser U, Heidecker B. Eosinophilic granulomatosis with polyangiitis (EGPA) with low activity EBV replication during the COVID 19 pandemic. Int J Cardiol Heart Vasc 2022; 39:100968.
Feb 10, 2022Eosinophilic granulomatosis with polyangiitis (EGPA) with low activity EBV replication during the COVID 19 pandemic.
Feb 10, 2022Int J Cardiol Heart Vasc 2022; 39:100968
Mueller Melina, Poller Wolfgang, Klingel Karin, Neumann Thomas, Landmesser Ulf, Heidecker Bettina
Anti-interleukin-23 directed therapy and the recurrence of severe allergic asthma
Schmiedeberg K, Rassouli F, von Kempis J, Rubbert-Roth A. Anti-interleukin-23 directed therapy and the recurrence of severe allergic asthma. Rheumatology (Oxford) 2022
Feb 8, 2022Anti-interleukin-23 directed therapy and the recurrence of severe allergic asthma
Feb 8, 2022Rheumatology (Oxford) 2022
Schmiedeberg Kristin, Rassouli Frank, von Kempis Johannes, Rubbert-Roth Andrea
Retroperitoneal Mass: Lymphoma as Differential Diagnosis to Retroperitoneal Fibrosis: Case Report
Nussberger M, Kim C, Cogliatti S, Neumann T, Müllhaupt G. Retroperitoneal Mass: Lymphoma as Differential Diagnosis to Retroperitoneal Fibrosis: Case Report. Springerplus 2022; 2022
Jan 7, 2022Retroperitoneal Mass: Lymphoma as Differential Diagnosis to Retroperitoneal Fibrosis: Case Report
Jan 7, 2022Springerplus 2022; 2022
Nussberger Madalina, Kim Chan-Hi Olaf, Cogliatti S, Neumann T, Müllhaupt Gautier
Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA.
Schmiedeberg K, Abela I, Pikor N, Vuilleumier N, Schwarzmueller M, Epp S, Pagano S, Grabherr S, Patterson A, Nussberger M, Trkola A, Ludewig B, von Kempis J, Rubbert-Roth A. Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA. RMD Open 2022; 8
Jan 1, 2022Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA.
Jan 1, 2022RMD Open 2022; 8
Schmiedeberg Kristin, Abela Irene A, Pikor Natalia, Vuilleumier Nicolas, Schwarzmueller Magdalena, Epp Selina, Pagano Sabrina, Grabherr Sarah, Patterson Angelica Brooke, Nussberger Madalina, Trkola Alexandra, Ludewig Burkhard, von Kempis Johannes, Rubbert-Roth Andrea
Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel).
Mueller R, Schulze-Koops H, Furst D, Cohen S, Kwok K, Wang L, Killeen T, von Kempis J. Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel). Clin Rheumatol 2022; 41:1045-1055.
Jan 1, 2022Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel).
Jan 1, 2022Clin Rheumatol 2022; 41:1045-1055
Mueller Ruediger B, Schulze-Koops Hendrik, Furst Daniel E, Cohen Stanley B, Kwok Kenneth, Wang Lisy, Killeen Tim, von Kempis Johannes
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials
Burmester G, Liu J, Mccaskill R, Lertratanakul A, Lippe R, Lesser E, Rubbert-Roth A, Salvarani C, Azevedo V, Goupille P, Nash P, Blanco R, Winthrop K, Ruderman E. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials. Rheumatol Ther 2021
Dec 30, 2021Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials
Dec 30, 2021Rheumatol Ther 2021
Burmester Gerd R, Liu John, Mccaskill Reva M, Lertratanakul Apinya, Lippe Ralph, Lesser Elizabeth, Rubbert-Roth Andrea, Salvarani Carlo, Azevedo Valderilio F, Goupille Philippe, Nash Peter, Blanco Ricardo, Winthrop Kevin, Ruderman Eric M
Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study
Rubbert-Roth A, Vuilleumier N, Ludewig B, Schmiedeberg K, Rottländer Y, Pirker I, von Kempis J (2022). Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study.
Dec 28, 2021Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study
Dec 28, 2021ACR Converence 2021
Rubbert-Roth Andrea, Vuilleumier Nicolas, Ludewig Burkhard, Schmiedeberg Kristin, Rottländer Yella, Pirker Ian, von Kempis Johannes